Outrage has erupted among health experts over news that the Centers for Disease Control and Prevention is still eager to fund a widely condemned vaccine trial that would expose newborns in Guinea-Bissau to hepatitis B, putting them at high risk of a lifelong infection, which can lead to liver cirrhosis, liver cancer, and premature death.
The trial was suspended in January after its unethical design came to light and drew international outcry. Although the trial is still halted, staff of the CDC director’s office told the agency’s budget office in late September to set aside $1.6 million to fund the trial, according to a report by Rolling Stone. The money was to be pulled from funding for the CDC’s global health security programs, which might otherwise go toward efforts like combating the Ebola outbreak currently raging in the Democratic Republic of the Congo.
The Department of Health and Human Services, which oversees the CDC, did not respond to a request for comment from Ars Technica.
AI coding agents generate more code, but not more software
October 9, 2026
PC shipments fall 20.1 percent in “sharpest decline” since Q1 2023
October 9, 2026
AI disqualification yields new Nikon Small World in Motion winner
October 9, 2026
Your artwork could be featured in the next Debian release
October 9, 2026
Starlink spectrum deal boosts Musk plan to beat AT&T, T-Mobile, and Verizon
October 9, 2026
Microsoft barred from sponsoring foreign workers for US residency
October 9, 2026
Trump announces deal for Russian diesel as Zelensky criticises 'gift to Putin'
October 9, 2026
In The Age Of AI Itineraries, Interrail Retires Eurail And Sells The Unplanned
October 9, 2026
Intel Stock Has Made A Strong Comeback. Here’s How To Play It
October 9, 2026
Income Tax Identity Theft Victims Face Long Refund Delays
October 9, 2026